

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Neurizon Therapeutics Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Marcus Hughes
<b>Date of last notice</b>	2 January 2026

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<p><b>Mr Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</b></p> <p>Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities</p> <p><b>Ms Antoinette Quinlan</b></p> <p>Spouse of Marcus Hughes</p>
<b>Date of change</b>	29 January 2026

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><u>Direct</u></p> <ul style="list-style-type: none"> <li>- 12,360,746 fully paid ordinary shares</li> <li>- 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032</li> </ul> <p><u>Indirect - Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 2,085,895 fully paid ordinary shares</li> </ul> <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> <li>- 423,895 fully paid ordinary shares</li> </ul>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	<p><u>Direct</u> 750,000 fully paid ordinary shares</p>
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.08 per Share (\$60,000.00)
<b>No. of securities held after change</b>	<p><u>Direct</u></p> <ul style="list-style-type: none"> <li>- 13,110,746 fully paid ordinary shares</li> <li>- 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032</li> </ul> <p><u>Indirect - Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 2,085,895 fully paid ordinary shares</li> </ul> <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> <li>- 423,895 fully paid ordinary shares</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in the Entitlement Offer as announced on 23 December 2025.</p>
---	---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.